Skip to main content

Table 4 Demographics and baseline characteristics in the 1-year observational therapeutic study

From: Remission in schizophrenia: results of cross-sectional with 6-month follow-up period and 1-year observational therapeutic studies in an outpatient population

Characteristics Risperidone (long-acting, injectable) (RLAI) group Routine treatment group
Number of patients 42 35
Sex: male/female 18/24 16/19
Age (SD) 43.7 (13.4) 45.4 (14.2)
Duration of disease (SD) 16.8 (11.7) 15.7 (12.3)
Number of previous hospitalizations (SD) 4.7 (2.5) 4.2 (2.8)
Paranoid schizophrenia:   
Continuous course 15/35.7% 11/31.4%
Episodic course with progressive and stable deficit 15/35.7% 13/37.1%
Remittent course 0 0
Hebephrenic schizophrenia 0 0
Catatonic schizophrenia 1/2.4% 1/2.9%
Undifferentiated schizophrenia 3/7.1% 2/5.7%
Residual schizophrenia 5/11.9% 6/17.1%
Simple schizophrenia 3/7.1% 2/5.7%
Schizoaffective disorder 0 0
PANSS total score (SD) 66.1 (10.7) 68.7 (12.3)
PANSS positive score (items 1 to 7) (SD) 14.5 (4.5) 16.0 (5.1)
PANSS negative score (items 8 to 14) (SD) 18.8 (4.3) 19.1 (4.8)
PANSS general score (items 15 to 30) (SD) 33.1 (5.4) 35.3 (6.8)
Simpson-Angus scale score (SD) 4.9 (6.3) 5.1 (6.1)
PSP score (SD) 52.0 (12.3) 51.3 (13.1)
ROMI score   
Compliance subscale 14.9 (2.3) 15.4 (2.6)
Non-compliance subscale 17.1 (3.3) 16.4 (4.1)
  1. No significant differences between groups.
  2. PANSS = Positive and Negative Syndrome Scale; PSP = Personal and Social Performance; ROMI = Rating of Medication Influences.